19Aprile2017 PaolaRogliani

PAOLAROGLIANI

ProfessoreAssociato

Malattiedell'ApparatoRespiratorio-MED/10-

DipartimentodiMedicinadeiSistemi

UniversitàdiRoma“TorVergata”

ViaMontpellier,1–00133-Roma,Italia

paola.rogliani@uniroma2.it

Luogodinascita Napoli

Datadinascita 19-09-1970

Cittadinanza Italiana

Statocivile Coniugata

• Direttore della di Scuola di Specializzazione in “Malattie dell’Apparato Respiratorio”,

DipartimentodiMedicinadeiSistemi,UniversitàdegliStudidiRoma“TorVergata”.

• Direttore (ff) della UOC di Malattie dell’Apparato Respiratorio, Dipartimento Clinico di

Medicina,“PoliclinicoTorVergata”Roma.

19Aprile2017 PaolaRogliani

Luglio1988 MaturitàClassicaconilmassimodeivoti.

Ottobre1994 LaureainMedicinaeChirurgiapressol’UniversitàdeglistudidiRoma“TorVergata”con110/110elode.

Dicembre1994 Abilitazioneall’eserciziodellaprofessionemedico-chirurgicanellapressolaSecondaUniversitàdeglistudidiNapolicon90/90.

Novembre1998 Specializzazionein“Malattiedell’ApparatoRespiratorio”pressol’UniversitàdeglistudidiRoma“TorVergata”con50/50elode.

Gennaio1999 BorsadiStudiodiPerfezionamentoall’estero-legge398/89-areadisciplinaregruppoB(ScienzeMedicheApplicate),gen-dic1999.

Novembre1999 Ricercatoreperilsettorescientifico-disciplinareMED/10,Malattiedell’ApparatoRespiratorio,pressolaFacoltàdiMedicinaeChirurgiadell’UniversitàdegliStudidiRoma“TorVergata”.

Luglio2006 Attribuzionecondecretorettoraledeltitolodi“ProfessoreAggregato”.

Dicembre2012 ProfessoreAssociatononconfermato,MED/10,Malattiedell’ApparatoRespiratorio,pressolaFacoltàdiMedicinaeChirurgiadell’UniversitàdegliStudidiRoma“TorVergata”,DipartimentodiMedicinadeiSistemi.

2013-2015 Direttore/CoordinatoreScuoladiSpecializzazioneinMedicinadelleSport,UniversitàdegliStudidiRoma“TorVergata”

2015-presente Direttore/CoordinatoreScuoladiSpecializzazionein“Malattiedell’ApparatoRespiratorio”,UniversitàdegliStudidiRoma“TorVergata”

AttivitàScientificaediRicerca

Nov/1989-Nov/1991 InternapressoilDipartimentodiBiochimicaeBiofisica“F.Cetrangolo”dellaSecondaUniversitàdeglistudidiNapolidirettadalProf.GennaroDellaPietra.

Gen/1994-Dic/1996 Internapressoillaboratoriodi“Cardiologiamolecolareecellulare”dell’UniversitàdeglistudidiRoma“TorVergata”direttodalDr.PaoloDiNardo.

Gen/1997-Dic/1998 VisitingFellowpressolaPulmonaryandCriticalCareMedicineBranch,pressol’NHLBIdell’NationalInstituteofHealth(NIH)Bethesda,MD–USA-direttadalDr.JoelMoss.

19Aprile2017 PaolaRogliani

Gen/1999-Ago/2000 VisitingFellowpressoil“LaboratoryofMolecularImmunology”,pressol’NHLBIdell’NationalInstituteofHealth(NIH)Bethesda,MD–USA-direttodalDrWarrenJLeonard.

Sett/2000-Dic/2012 RicercatorenelgruppodisciplinareMED10"Malattiedell’ApparatoRespiratorio”,DipartimentodiMedicinaInterna,UniversitàdeglistudidiRoma“TorVergata”.

Dic/2012-presente ProfessoreAssociatonelgruppodisciplinareMED10"Malattiedell’ApparatoRespiratorio”,DipartimentodiMedicinadeiSistemi,UniversitàdeglistudidiRoma“TorVergata”.

LINEEdiRICERCA

• Patologiaostruttivaedismetabolismo

• Lecomorbilitànellapatologiaostruttivabronchialecronica(asmaeBPCO):epidemiologiaepossibilimeccanismipatogenetici.

• Valutazionepreclinicaeclinicadeinuovifarmaciperiltrattamentodellapatologiaostruttivabronchialecronica(BPCOeasma).

• Basistrutturaliefunzionalidellasuscettibilitàgeneticaallepatologieinterstizialipolmonari

• Enfisemapolmonare:a1-Antitripsinaeilsuoruoloinibitoredell’elastasineutrofila.

PREMI/AWARD

2010 PremioMigliorricercatoreunder40dell’XI°CongressoNazionaledellaPneumologia

COMITATIEDITORIALI

2013-presente EditorialBoardofArsPneumologica

2013-presente EditorialBoardofCOPDResearchandPractice

2015-presente EditorialBoardofPulmonaryPharmacologyandTherapeutics

2015-presente EditorialBoardofJournalofPulmonologyandRespiratoryResearch

2016-presente EditorialBoardofInternationalJournalofChronicObstructivePulmonaryDisease

19Aprile2017 PaolaRogliani

SOCIETA’SCIENTIFICHE

• Sociodell’EuropeanRespiratorySociety(ERS)

• SociodellaSocietàItalianadiMedicinaRespiratoria(SIMeR),SegretarioelettoGruppoClinicamandato2016/2018

COLLABORAZIONISCIENTIFICHE

2007-Presente CollaborazionediricercaconilSacklerInstituteofPulmonaryPharmacology,King’sCollegeLondon,profClivePage.

2007-Presente CollaborazionediricercaconlaSezionediFarmacologiaLeonardoDonatelli,DipartimentodiMedicinaSperimentaleFacoltàdiMedicinaeChirurgiaIIUniversitàdegliStudidiNapoli“Vanvitelli”,Prof.ssaMariaGabriellaMatera

2008-Presente CollaborazionediricercaconlaDivisionofRespirology,WesternUniversity,London,Ontario,Canada,ProfMarcoMura.

2010-Presente CollaborazionediricercaconleMalattieRespiratorieeTrapiantoPolmonare,UniversitàdiSiena,Prof.ssaPaolaRottoli

PARTECIPAZIONEAUNITÀOPERATIVEDIRICERCA

- Componentedell’unitàdiricercadelprogetto“Geneticadellacardiomiopatiaipertrofica“GrantCNR92.0330711,9303391.11

- Componentedell’unitàdiricercadelprogetto“RoleofNitricOxideinthepathogenesisoflungdisease”GrantNIH201HL02537.04PCCMB

- Componentedell’unitàdiricercadelprogetto“AnalysisofHLA-DPassociationwithberylliumdiseasesusceptibilityinpooledexposedpopulation”GrantDE-FG02-02ER63416

- Componentedell’unitàdiricercadelprogetto“RoleofpeptidebindingandintracellularsignallingdiversityofmajorhistocompatibilitycomplexgenesinT-cellactivationanddifferentiationinchronicgranulomatousdisorders”Grant(ISS-NIH)CONV.N.530/F-A15

- Componetedell’unitàdiricercadelprogetto“IdentificazionedegliagretopiperigenidelComplessoMaggiorediIstocompatibilitàdiclasseIIcoinvoltinellasuscettibilitàallasarcoidosienellaevoluzionefibroticadellamalattia”PRIN2004067923_006

- ResponsabilediUnitàOperativadiricercadelprogetto“PiattaformaItalianaperlostudiodelle polimorbilità: scenario epidimiologico, aspetti clinici e farmacologici, prospettiva digenereecontestofarmaco-economico”,ISSPROGRAMMACCM2012

19Aprile2017 PaolaRogliani

- Componetedell’unitàdiricercadelprogettodell’UniversitàdiRomaTorVergata,ProgettoMIUR Smart Cities: Smart domotics for safe and energy-aware assisted living – SEAL:Smart&safe,Energy-awareAssistedLiving,incollaborazioneconElicas.p.a.,BFTs.p.a.ecc.(2013)

- Project director in the research program on "Pharmacological investigation of theinteractionbetweentiotropiumbromideandolodaterolonthecontractiletoneofhumanbronchi",fundedbyBoehringerIngelheimInternationalGmbH(2015)

- Componetedell’unitàdiricercadelDipartimentodiMedicinadeiSistemidell'UniversitàdiRoma "Tor Vergata" del Progetto TELETHON "Clinical efficacy of NIV and modafinil onexcessivedaytimesleepiness:amulticenter,randomized,double-blind,placebo-controlledclinicaltrialinDM1"

- Responsabiledelprogettodi ricercasullo"Studiosumodelloex-vivodibroncoumanodiinterazione farmacologicaesul sinergismotracorticosteroidi, LABAeLAMAnellediverseassociazioni",finanziatodaCHIESIfarmaceuticispa(2016)

- Principal investigator, Ricerca Scientifica di Ateneo 2015 "Consolidate the Foundations",progetto dal titolo" Human bronchial hyperresponsiveness in a human ex vivomodel ofdiabetesmellitus"

BREVETTI/INVENZIONI

2012 Software applicativo per smartphone, tablet e calcolatori elettronici, “COPDCoRi:

applicazione non invasiva per la stima e la previsione del rischio di patologia coronarica nei

pazientiaffettidabroncopneumopatiacronicaostruttiva(BPCO)”.(Autori:P.Rogliani,MGMatera,

FRomeo,L.Calzetta;depositatoallaSIAEn.2013001671)

19Aprile2017 PaolaRogliani

ATTIVITÀCLINICA

12/2000-12/2002 AttivitàassistenzialeinqualitàdiDirigentemedicodiIlivellopressoilRepartodiMalattiedell’ApparatoRespiratoriodellaDivisioneclinicizzatadiMalattieRespiratoriedirettadalProf.C.Saltini,UniversitàdeglistudidiRoma“TorVergata”,pressol’IRCCS“L.Spallanzani”Roma.

1/2003-07/2003 AttivitàassistenzialeinqualitàdiDirigentemedicodiIlivellopressol’AmbulatoriodiMalattiedell’ApparatoRespiratoriodellaDivisioneclinicizzatadiMalattieRespiratoriedirettadalProf.C.Saltini,UniversitàdeglistudidiRoma“TorVergata”,pressol’IRCCS“L.Spallanzani”Roma

1/2003-06/2004 ResponsabiledelDay-HospitaldedicatoalloStudiodelleInterstiziopatiePolmonaripressolaDivisioneclinicizzatadiMalattieRespiratorie,UniversitàdeglistudidiRoma“TorVergata”,pressol’IRCCS“L.Spallanzani”Roma.

7/2004-2007 Incaricoaifiniassistenzialipressol’ambulatoriodiMalattieRespiratoriedellaDisciplinadiMalattieRespiratoriedirettadalProf.C.Saltini,AreaFunzionaleAggregatadiMedicina,AziendaOspedalieraUniversitaria“PoliclinicoTorVergata”

1/2006-12/2007 ResponsabiledelServizioConsulenzePneumologichedellaDisciplinadiMalattieRespiratorie,AreaFunzionaleAggregatadiMedicina,AOU“PoliclinicoTorVergata”

11/2007-11/2011 ResponsabiledelDay-HospitaldedicatoalloStudiodelleInterstiziopatiePolmonariedell’ambulatoriodella“Fibrosipolmonareemalattierare”dellaUOCdiMalattieRespiratorie,AreaFunzionaleAggregatadiMedicina,AziendaOspedalieraUniversitaria“PoliclinicoTorVergata”

12/2011-Sett/2013 ResponsabiledelRepartodiMalattiedell’ApparatoRespiratoriodellaUOCdiMalattieRespiratoriePoliclincicoTorVergata,Roma

1/2006-presente Dirigentedell’UnitàOperativaSemplice(UOS)di“EndoscopiaRespiratoria”dellaUOCdiMalattieRespiratorie,DipartimentoClinicodiMedicina,“PoliclinicoTorVergata”

11/2015-presente Direttore(ff)dell’UnitàOperativaComplessa(UOC)diMalattieRespiratorie,DipartimentoClinicodiMedicina,“PoliclinicoTorVergata”

19Aprile2017 PaolaRogliani

ATTIVITÀDIDATTICA

2013-2015 Direttore/CoordinatoredellaScuoladispecializzazionein“MedicinadelloSport”UniversitàdeglistudidiRoma“TorVergata”

2015-presente Direttore/CoordinatoreScuoladiSpecializzazionein“Malattiedell’ApparatoRespiratorio”,UniversitàdegliStudidiRoma“TorVergata”

A.A.2004-presente Incaricod’insegnamentodiMalattiedell’ApparatoRespiratoriopressoilCorsodiLaureaSpecialisticainScienzedellaRiabilitazione,dell’UniversitàdegliStudidiRoma“TorVergata”

A.A.2005-presente Incaricod’insegnamentodiMalattiedell’ApparatoRespiratoriopressoilCorsodiLaureainScienzeInfermieristiche,dell’UniversitàdegliStudidiRoma“TorVergata”

A.A.2006-presente CoordinatoredelCorsoIntegratodi“Malattiedell’ApparatoRespiratorioeCardiovascolare”delCorsodiLaureaspecialisticainScienzeeTecnichedelleattivitàmotoriePreventiveedAdattate,dell’UniversitàdegliStudidiRoma“TorVergata”

A.A.2006-2015 Incaricod’insegnamentodiFisiopatologiaRespiratoria(modulo),CorsoIntegratoPatologiaSistematicaI,pressoilCorsodiLaureainMedicinaeChirurgia,dell’UniversitàdegliStudidiRoma“TorVergata”

A.A.2015-presente Incaricod’insegnamentodiMalattiedell’ApparatoRespiratorio,CorsoIntegratoPatologiaSistematicaI,pressoilCorsodiLaureainMedicinaeChirurgia,dell’UniversitàdegliStudidiRoma“TorVergata”

A.A.1995-1998 AttivitàdidatticaconseminarimonotematicisullaPatologiaRespiratoriapressolaScuoladiSpecializzazioneinEndocrinologiaelaScuoladiSpecializzazioneinGeriatria

A.A.2000-presente AttivitàtutorialeperlaformazionescientificaeclinicadeglistudentidelCorsodiLaureainMedicinaeChirurgia,UniversitàdegliStudidiRoma-“TorVergata”

A.A.2000-presente GuidanellaelaborazionedelletesidispecializzazioneedattivitàtutorialeperlaformazionescientificaeclinicadeglispecializzandidellaScuoladiMalattiedell’ApparatoRespiratoriodell’UniversitàdegliStudidiRoma“TorVergata”

19Aprile2017 PaolaRogliani

A.A.2000-presente Incaricod’insegnamentodiMetodologiaClinicaediMalattieRespiratoriepressolaScuoladiSpecializzazioneinMalattiedell’ApparatoRespiratoriodell’UniversitàdegliStudidiRoma“TorVergata”

A.A.2000-presente Incaricod’insegnamentodiMalattieRespiratoriepressolaScuoladiSpecializzazioneinEndocrinologiaeMalattieMetabolichedell’UniversitàdegliStudidiRoma“TorVergata”

A.A.2002-presente Incaricod’insegnamentopressolaScuoladiSpecializzazioneinGeriatriadell’UniversitàdegliStudidiRoma“TorVergata”

A.A.2006-presente Incaricod’insegnamentodiRiabilitazioneCardiorespiratoriapressolaScuoladiSpecializzazioneinCardiologiadell’UniversitàdegliStudidiRoma“TorVergata”

A.A.2006-2007 Incaricod’insegnamentodiMalattieRespiratoriepressolaScuoladiSpecializzazioneinMedicinadelloSportdell’UniversitàdegliStudidiRoma“TorVergata”

A.A.2007-presente Incaricod’insegnamentodiFisiopatologiaRespiratoriapressolaScuoladiSpecializzazioneinChirurgiaToracicadell’UniversitàdegliStudidiRoma“TorVergata”

A.A.2007-presente Incaricod’insegnamentodiFisiopatologiaRespiratoriapressolaScuoladiSpecializzazioneinMedicinaInternadell’UniversitàdegliStudidiRoma“TorVergata”

PARTECIPAZIONEALCOLLEGIODEIDOCENTIDIDOTTORATO

A.A.2006-2011 DottoratodiRicerca"FisiopatologiaSperimentaleeMedicinaMolecolare"UniversitàdegliStudidiROMA"TorVergata"

A.A.2011-presente DottoratodiRicerca"MedicinaSperimentaleedeiSistemi"UniversitàdegliStudidiROMA"TorVergata".

ATTIVITA’DIDATTICAUFFICIALEPRESSOATENEIESTERI

A.A.2009-2012 Incaricod’insegnamentodiMalattiedell’ApparatoRespiratorio,CorsoIntegratoPatologiaSistematicaI,pressoilCorsodiLaureainMedicinaeChirurgiaUniversità"NostraSignoradelBuonConsiglio",Tirana,Albania

19Aprile2017 PaolaRogliani

ATTIVITA’ISTITUZIONALEd’ATENEO

2013-presente MembrodelPresidioQualitàdiAteneo(PQA),MacroareadiMedicinaeChirurgia,UniversitàdegliStudidiROMA"TorVergata".

2016-presente Commissionepariteticadocenti/studenti,FacoltàdidiMedicinaeChirurgia,UniversitàdegliStudidiROMA"TorVergata".

2016-presente MembrodellaCommissioneperlaValorizzazionedeiRisultatidellaRicercaeperilTrasferimentoTecnologicoincomposizione'Brevetti',UniversitàdegliStudidiROMA"TorVergata".

19Aprile2017 PaolaRogliani

PUBBLICAZIONI1) MaioneF,IaccarinoF,SirignanoM,RoglianiP,DellaPietraF.“Studiodiunavariantediα1-

Antitripsina”.Acc.DiScienzaMedicheeChirurgiche(VolCXLVIIfeb.1993)

2) Rossi P. - Senis L. - Contini A. - Nardecchia B. - Rogliani P. - Bisogni V. - Rossi S.

“Osservazioni clinico-epidemiologiche sulla tubercolosi polmonare nei pazienti

extracomunitari ricoverati”. IgieneeSanitàPubblica,vol.52,n.4, luglio-agosto1996,pp.

271-280.

3) DiNardoP,FiaccaventoR,NataliA,MinieriM,SampaolesiM,FuscoA,JanmotC,CudaG,

CarboneA,RoglianiP,PeruzziG.“Embryonicgeneexpressioninnonoverloadedventricles

of hereditary hypertrophic cardiomyopathic hamsters”. Lab Invest. 1997 Nov;77(5):489-

502.

4) MineoTC,PompeoE,SimonettiG,SabatoAF,TuraniF,RoglianiP,DePadovaF,NofroniI.

“Unilateral thoracoscopic reduction pneumoplasty for asymmetric emphysema”. Eur J

CardiothoracSurg.1998Jul;14(1):33-9.

5) NovoradovskyA,BrantlyML,WaclawiwMA,ChaudharyPP,IharaH,QiL,EissaNT,Barnes

PM,GabrieleKM,EhrmantrautME,RoglianiP,MossJ.“Endothelialnitricoxidesynthaseas

a potential susceptibility gene in the pathogenesis of emphysema in alpha1-antitrypsin

deficiency”.AmJRespirCellMolBiol.1999Mar;20(3):441-7.

6) Mineo TC, Pompeo E, Rogliani P, Villaschi S, Pistolese C, Simonetti G. “Thoracoscopic

reduction pneumoplasty for severe emphysema: do pleural adhesions affect outcome?”

ThoracCardiovascSurg.1999Oct;47(5):288-92.

7) TesauroM,ThompsonWC,RoglianiP,QiL,ChaudharyPP,MossJ.“Intracellularprocessing

of endothelial nitric oxide synthase isoforms associated with differences in severity of

cardiopulmonary diseases: cleavage of proteinswith aspartate vs. glutamate at position

298”.ProcNatlAcadSciUSA.2000Mar14;97(6):2832-5

8) MineoTC,PompeoE,RoglianiP,DauriM,TuraniF,BolleroP,MagliocchettiN.“Effectof

lungvolumereductionsurgeryforsevereemphysemaonrightventricularfunction”.AmJ

RespirCritCareMed.2002Feb15;165(4):489-94.

9) AmicosanteM,BerrettaF,FranchiA,RoglianiP,DottiC,LosiM,DweikR,SaltiniC.“HLA-

DP-unrestricted TNF-alpha release in beryllium-stimulatedperipheral bloodmononuclear

cells”.EurRespirJ.2002Nov;20(5):1174-8.

19Aprile2017 PaolaRogliani

10) RoglianiP,AmicosanteM,BerrettaF,DottiC,BocchinoM,O'DonnellKM,SaltiniC.Roleof

theHLA-DPglu69andtheTNFalphaTNFalpha2genemarkersinsusceptibilitytoberyllium

hypersensitivity.IntJImmunopatholPharmacol.2004May-Aug;17(2Suppl):3-10

11) DottiC,D'ApiceMR,RoglianiP,NovelliG,SaltiniC,AmicosanteM.AnalysisofTNF-alpha

promoter polymorphisms in the susceptibility to beryllium hypersensitivity. Sarcoidosis

VascDiffuseLungDis.2004Mar;21(1):29-34)

12) PompeoE,MineoD,BolleroP,RoglianiP,AmbrogiV,MineoTC.Completion lobectomy

after bilateral lung volume reduction for emphysema: salvage option or fancy? J Thorac

CardiovascSurg.2004Apr;127(4):1212-4.

13) Pompeo E, Mineo D, Rogliani P, Sabato AF, Mineo TC. Feasibility and results of awake

thoracoscopic resection of solitary pulmonary nodules. Ann Thorac Surg. 2004

Nov;78(5):1761-8

14) MineoTC,PompeoE,MineoD,RoglianiP,LeonardisC,NofroniI.Resultsofunilaterallung

volumereductionsurgery inpatientswithdistinctheterogeneityofemphysemabetween

lungs.JThoracCardiovascSurg.2005Jan;129(1):73-9

15) Amicosante M, Berretta F, Rossman M, Butler RH, Rogliani P, van den Berg-Loonen E,

SaltiniC.IdentificationofHLA-DRPhebeta47asthesusceptibilitymarkerofhypersensitivity

to beryllium in individuals lacking the berylliosis-associated supratypic marker HLA-

DPGlubeta69.RespirRes.2005Aug14;6:94.

16) Cazzola M, Matera MG, Rogliani P, Page C. Treating systemic effects of COPD. Trends

PharmacolSci.2007Oct;28(10):544-50.

17) Cazzola M, Rogliani P, Curradi G. Bacterial extracts for the prevention of acute

exacerbationsinchronicobstructivepulmonarydisease:apointofview.RespirMed.2008

Mar;102(3):321-7.

18) Rogliani P, Mura M, Porretta MA and Saltini C. New perspectives in the treatment of

idiopathicpulmonaryfibrosis.TherapeuticAdvancesinRespiratoryDisease2008;2;75

19) RoglianiP,MuraM,MattiaP,FerlosioA,FarinelliG,MariottaS,GrazianoP,PezzutoG,Ricci

A, Saltini C, Orlandi A. HRCT and histopathologic evaluation of fibrosis and tissue

destruction in IPF associated with pulmonary emphysema. Respir Med. 2008

Dec;102(12):1753-61

20) CazzolaM,MuraM,SegretiA,MatteiMA,RoglianiP.

19Aprile2017 PaolaRogliani

Eosinophilicpneumoniainanasthmaticpatienttreatedwithomalizumabtherapy:forme-

frusteofChurg-Strausssyndrome?Allergy.2009Sep;64(9):1389-90.

21) MateraMG,CalzettaL,ParascandoloV,CurradiG,RoglianiP,CazzolaM.Relaxanteffectof

brainnatriureticpeptideinnonsensitizedandpassivelysensitizedisolatedhumanbronchi.

PulmPharmacolTher.2009Dec;22(6):478-82.

22) Cazzola M, Rogliani P, Curradi G, Segreti A, Ciaprini C, Pezzuto G, Saltini C. A pilot

comparisonofheliumdilutionandplethysmographiclungvolumestoassesstheimpactof

a long-actingbronchodilatoron lunghyperinflation inCOPD.PulmPharmacolTher.2009

Dec;22(6):522-5.

23) ComandiniA,Rogliani P,NunziataA, CazzolaM,CurradiG, Saltini C. Biomarkersof lung

damage associated with tobacco smoke in induced sputum. Respir Med. 2009

Nov;103(11):1592-613.

24) RoglianiP,CurradiG,MuraM,LauroD,FedericiM,GalliA,SaltiniC,CazzolaM.Metabolic

syndromeandriskofpulmonaryinvolvement.RespirMed.2010Jan;104(1):47-51.

25) RicciA,Mariotta S,Bronzetti E, BrunoP,Vismara L,DeDominicisC, LaganàB, PaoneG,

MuraM,RoglianiP,MastrangeldoM,SciacchitanoS,SaltiniC.SerumCA15-3isincreased

inpulmonaryfibrosis.SarcoidosisVascDiffuseLungDis.2009Jul;26(1):54-63.

26) SergiacomiG,BolacchiF,CadioliM,AngeliML,Fucci F,CruscoS,RoglianiP,Pezzuto G,

RomeoF,MarianoE,SimonettiG.Combinedpulmonaryfibrosisandemphysema:3Dtime-

resolvedMRangiographicevaluationofpulmonaryarterialmeantransittimeandtimeto

peakenhancement.Radiology.2010Feb;254(2):601-8.

27) CazzolaM,CalzettaL,BettoncelliG,NovelliL,CricelliC,RoglianiP.

Asthmaandcomorbidmedicalillness.EurRespirJ.2011Jul;38(1):42-9.

28) MateraMG,CalzettaL,RoglianiP,BardaroF,PageCP,CazzolaM.Evaluationoftheeffects

of the R- and S-enantiomers of salbutamol on equine isolated bronchi. Pulm Pharmacol

Ther.2011Apr;24(2):221-6.

29) CazzolaM,SegretiA,BettoncelliG,Calzetta L,CricelliC,PasquaF,RoglianiP.Change in

asthma and COPD prescribing by Italian general practitioners between 2006 and 2008.

PrimCareRespirJ.2011Sep;20(3):291-8.

30) PompeoE,RoglianiP,TacconiF,DauriM,SaltiniC,NovelliG,MineoTC;AwakeThoracic

Surgery Research Group. Randomized comparison of awake nonresectional versus

19Aprile2017 PaolaRogliani

nonawake resectional lung volume reduction surgery. J Thorac Cardiovasc Surg. 2012

Jan;143(1):47-54.e1.

31) Cazzola M, Calzetta L, Bettoncelli G, Cricelli C, Romeo F, Matera MG, Rogliani P.

Cardiovascular disease in asthma and COPD: A population-based retrospective cross-

sectionalstudy.RespirMed.2012Feb;106(2):249-56.

32) MuraM, Porretta MA, Bargagli E, Sergiacomi G, Zompatori M, Sverzellati N, Taglieri A,

Mezzasalma F, Rottoli P, Saltini C, Rogliani P. Predicting survival in newly diagnosed

idiopathicpulmonaryfibrosis:a3-yearprospectivestudy.EurRespirJ.2012Jul;40(1):101-

9.

33) CazzolaM,CalzettaL,RoglianiP,LauroD,NovelliL,PageCP,KanabarV,MateraMG.High

glucose enhances responsiveness of human airways smooth muscle via the Rho/ROCK

pathway.AmJRespirCellMolBiol.2012Oct;47(4):509-16.

34) CazzolaM,CapuanoA,RoglianiP,MateraMG.Bacteriallysatesasapotentiallyeffective

approach in preventing acute exacerbation of COPD. Curr Opin Pharmacol. 2012

Jun;12(3):300-8.

35) Matera MG, Calzetta L, Passeri D, Rogliani P, Orlandi A. Epithelial-smooth muscle

cooperation is needed for brain natriuretic peptide-dependent bronchorelaxant activity.

PulmPharmacolTher.2012Sep21.

36) CazzolaM,RoglianiP,SegretiA,MateraMG.AnupdateonbronchodilatorsinPhaseIand

IIclinicaltrials.ExpertOpinInvestigDrugs.2012Oct;21(10):1489-501.

37) CazzolaM,SegretiA,RoglianiP.Comparativeeffectivenessofdrugsforchronicobstructive

pulmonarydisease.DrugsToday(Barc).2012Dec;48(12):785-94.

38) Pompeo E, Rogliani P, Cristino B, Schillaci O, Novelli G, Saltini C. Awake Thoracoscopic

BiopsyofInterstitialLungDisease.AnnThoracSurg.2013Feb;95(2):445-52.

39) Cazzola M, Segreti A, Stirpe E, Puxeddu E, Ora J, Rogliani P, Matera MG. Effect of an

additionaldoseofindacaterolinCOPDpatientsunderregulartreatmentwithindacaterol.

RespirMed.2013Jan;107(1):107-11.

40) CazzolaM,SegretiA,CalzettaL,RoglianiP.

Comorbidities of asthma: current knowledge and future researchneeds. CurrOpinPulm

Med.2013Jan;19(1):36-41-

19Aprile2017 PaolaRogliani

41) RoglianiP,CalzettaL,RendinaEA,MassulloD,DauriM,RinaldiB,CapuanoA,MateraMG.

The influence of propofol, remifentanil and lidocaine on the tone of human bronchial

smoothmuscle.PulmPharmacolTher.2013Jun;26(3):325-

42) CazzolaM, Page CP,Rogliani P,MateraMG. β2-Agonist Therapy in Lung Disease. Am J

RespirCritCareMed.2013Apr1;187(7):690-6.

43) Segreti A, Fiori E, Calzetta L, SabatiniM, Segreti V,Rogliani P, CazzolaM. The effect of

indacaterolduringanacuteexacerbationofCOPD.PulmPharmacolTher.2013Apr8.

44) CazzolaM, Rogliani P, Ruggeri P, Segreti A, Proietto A, Picciolo S, MateraMG. Chronic

treatmentwithindacaterolandairwayresponsetosalbutamolinstableCOPD.RespirMed.

2013Jun;107(6):848-53.

45) CazzolaM, Rogliani P, MateraMG. Aclidinium bromide/formoterol fumarate fixed-dose

combination for the treatment of chronic obstructive pulmonary disease. Expert Opin

Pharmacother.2013Apr;14(6):775-81.

46) CazzolaM, Rogliani P, Ruggeri P, Segreti A, Proietto A, Picciolo S, MateraMG. Chronic

treatmentwithindacaterolandairwayresponsetosalbutamolinstableCOPD.RespirMed.

2013Jun;107(6):848-53.

47) PompeoE,DauriM;AwakeThoracicSurgeryResearchGroup.Isthereanybenefitinusing

awake anesthesia with thoracic epidural in thoracoscopic talc pleurodesis? J Thorac

CardiovascSurg.2013Aug;146(2):495-7.

48) CalzettaL,PasseriD,KanabarV,RoglianiP,PageC,CazzolaM,MateraMG,OrlandiA.Brain

Natriuretic Peptide Protects Against Hyperreactivityof Human Asthmatic Airway Smooth

MuscleviaanEpithelialCellDependentMechanism.AmJRespirCellMolBiol.2013Sep27.

49) CalzettaL,PageCP,SpinaD,CazzolaM,RoglianiP, FaccioloF,MateraMG.Effectof the

mixed phosphodiesterase 3/4 inhibitor RPL554 on human isolated bronchial smooth

muscletone.JPharmacolExpTher.2013Sep;346(3):414-23.

50) CazzolaM,Calzetta L, LauroD,BettoncelliG,CricelliC,DiDanieleN,RoglianiP.Asthma

andCOPDinanItalianadultpopulation:roleofBMIconsideringthesmokinghabit.Respir

Med.2013Sep;107(9):1417-22.

51) RoglianiP,Ora J,CiapriniC,SenisL,StirpeE,CazzolaM.Effectof indacaterolonarterial

bloodgasesinpatientssufferingfromacuteexacerbationofCOPD.RespirMed.2013Nov

5.

19Aprile2017 PaolaRogliani

52) OraJ,CalzettaL,PezzutoG,SenisL,PaoneG,MariA,PortaloneS,RoglianiP,PuxedduE,

SaltiniC.A6MWTindextopredictO2flowcorrectingexerciseinducedSpO2desaturation

inILD.RespirMed.2013Dec;107(12):2014-21.

53) CazzolaM,RoglianiP,NovelliL,MateraMG.Inhaledcorticosteroidsforchronicobstructive

pulmonarydisease.ExpertOpinPharmacother.2013Dec;14(18):2489-99.

54) Segreti A, Fiori E, Calzetta L, SabatiniM, Segreti V,Rogliani P, CazzolaM. The effect of

indacaterol during an acute exacerbation of COPD. Pulm Pharmacol Ther. 2013

Dec;26(6):630-4.

55) CazzolaM,RoglianiP,RuggeriP,SegretiA,ProiettoA,PiccioloS,MateraMG.Chronic

treatmentwith indacaterol andairway response to salbutamol in stableCOPD.Respir

Med.2013Jun;107(6):848-53.

56) CazzolaM,RoglianiP,MateraMG.Aclidiniumbromide/formoterolfumaratefixed-dose

combination for the treatmentof chronicobstructivepulmonarydisease. ExpertOpin

Pharmacother.2013Apr;14(6):775-81.

57) Pompeo E, DauriM; Awake Thoracic Surgery ResearchGroup. Is there any benefit in

using awake anesthesia with thoracic epidural in thoracoscopic talc pleurodesis? J

ThoracCardiovascSurg.2013Aug;146(2):495-7.

58) CalzettaL,PageCP,SpinaD,CazzolaM,RoglianiP,FaccioloF,MateraMG.Effectofthe

mixed phosphodiesterase 3/4 inhibitor RPL554 on human isolated bronchial smooth

muscletone.JPharmacolExpTher.2013Sep;346(3):414-23.

59) CazzolaM,CalzettaL,LauroD,BettoncelliG,CricelliC,DiDanieleN,RoglianiP.Asthma

and COPD in an Italian adult population: role of BMI considering the smoking habit.

RespirMed.2013Sep;107(9):1417-22.

60) OraJ,CalzettaL,PezzutoG,SenisL,PaoneG,MariA,PortaloneS,RoglianiP,PuxedduE,

Saltini C. A 6MWT index to predict O2 flow correcting exercise induced SpO2

desaturationinILD.RespirMed.2013Dec;107(12):2014-21.

61) Cazzola M, Rogliani P, Novelli L, Matera MG. Inhaled corticosteroids for chronic

obstructivepulmonarydisease.ExpertOpinPharmacother.2013Dec;14(18):2489-99

62) RoglianiP,OraJ,CiapriniC,SenisL,StirpeE,CazzolaM.

Effectofindacaterolonarterialbloodgasesinpatientssufferingfromacuteexacerbation

ofCOPD.RespirMed.2013Nov5.

63) MateraMG,CalzettaL,RoglianiP,CesarioA,CazzolaM.

19Aprile2017 PaolaRogliani

NewTreatmentsforCOPDintheElderly.CurrPharmDes.2014Mar14

64) MateraMG,RoglianiP,CazzolaM.

Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary

disease.ExpertOpinPharmacother.2014May;15(7):961-77

65) RoglianiP,CalzettaL,SegretiA,BarrileA,CazzolaM.Diabetesmellitusamongoutpatients

withCOPDattendingauniversityhospital.ActaDiabetol.2014Apr13

66) Calzetta L, Rogliani P, Cazzola M, Matera MG. Advances in asthma drug discovery:

evaluatingthepotentialofnasalcellsamplingandbeyond.ExpertOpinDrugDiscov.2014

Jun;9(6):595-607.Epub2014Apr22.

67) Segreti A, Stirpe E, Rogliani P, Cazzola M. Defining phenotypes in COPD: an aid to

personalizedhealthcare.MolDiagnTher.2014Aug;18(4):381-

68) CazzolaM, Calzetta L, Segreti A, Facciolo F,Rogliani P,MateraMG. Translational Study

SearchingforSynergybetweenGlycopyrroniumandIndacaterol.COPD.2014Sep15

69) MateraMG,Rogliani P, Calzetta L, CazzolaM. Phosphodiesterase Inhibitors for Chronic

ObstructivePulmonaryDisease:WhatDoestheFutureHold?Drugs.2014Oct10.

70) Segreti A, Calzetta L,Rogliani P, CazzolaM. Umeclidinium for the treatment of chronic

obstructivepulmonarydisease.ExpertRevRespirMed.2014Oct14:1-7.

71) MateraMG,RoglianiP,RinaldiB,CazzolaM. Umeclidiniumbromide+vilanterol for the

treatment of chronic obstructive pulmonary disease. Expert Rev Clin Pharmacol. 2015

Jan;8(1):35-41.

72) MateraMG,RoglianiP, CazzolaM. Indacaterol for the treatmentof chronicobstructive

pulmonarydisease.ExpertOpinPharmacother.2015Jan;16(1):107-15.

73) Cazzola M, Calzetta L, Page CP, Rogliani P, Facciolo F, Gavaldà A, Matera MG.

Pharmacological characterization of the interaction between aclidinium bromide and

formoterolfumarateonhumanisolatedbronchi.EurJPharmacol.2014Dec15;745:135-43

74) LipsiR,RoglianiP,CalzettaL,SegretiA,CazzolaM.Theclinicaluseofregenerativetherapy

inCOPD.IntJChronObstructPulmonDis.2014Dec12;9:1389-1396.eCollection2014.

75) MateraMG,CardaciV,CazzolaM,RoglianiP.

Safetyofinhaledcorticosteroidsfortreatingchronicobstructivepulmonarydisease.Expert

OpinDrugSaf.2015Jan5:1-9.

76) Rogliani P, Calzetta L, Ora J, Matera MG. Canakinumab for the treatment of chronic

obstructivepulmonarydisease.PulmPharmacolTher.2015Apr;31:15-27.

19Aprile2017 PaolaRogliani

77) MateraMG,RoglianiP,CazzolaM.QVA149(indacaterol/glycopyrronium)forthetreatment

of chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2015

May;16(7):1079-90.

78) Calzetta L, Cazzola M, Page CP, Rogliani P, Facciolo F, Matera MG. Pharmacological

characterizationoftheinteractionbetweenthedualphosphodiesterase(PDE)3/4inhibitor

RPL554andglycopyrroniumonhumanisolatedbronchiandsmallairways.PulmPharmacol

Ther.2015Apr18.

79) Calzetta L, Luongo L, Cazzola M, Page C, Rogliani P, Facciolo F, Maione S, Capuano A,

RinaldiB,MateraMG.ContributionofsensorynervestoLPS-inducedhyperresponsiveness

ofhumanisolatedbronchi.LifeSci.2015Apr24.

80) Rogliani P, Calzetta L, Ora J, Lipsi R, Segreti A,MateraMG, CazzolaM. Pharmacological

assessmentof theonsetofactionofaclidiniumandglycopyrroniumversus tiotropium in

COPDpatientsandhumanisolatedbronchi.EurJPharmacol.2015Aug15;761:383-90

81) Cazzola M, Rogliani P, Sanduzzi A, Matera MG. Influence of ethnicity on response to

asthmadrugs.ExpertOpinDrugMetabToxicol.2015Jul;11(7):1089-97.

82) Ricciardolo FL, Blasi F, Centanni S, Rogliani P. Therapeutic novelties of inhaled

corticosteroidsandbronchodilatorsinasthma.PulmPharmacolTher.2015Aug;33:1-10

83) PompeoE,RoglianiP,PalombiL,OrlandiA,CristinoB,DauriM;AwakeThoracicSurgery

Research Group (ATSRG). The complex care of severe emphysema: role of awake lung

volumereductionsurgery.AnnTranslMed.2015May;3(8):108.

84) Pompeo E, Cristino B, Rogliani P, Dauri M; Awake Thoracic Surgery Research Group

(ATSRG).Urgentawakethoracoscopictreatmentofretainedhaemothoraxassociatedwith

respiratoryfailure.AnnTranslMed.2015May;3(8):112.

85) CazzolaM, Calzetta L,MateraMG,Muscoli S,Rogliani P, Romeo F. Chronic obstructive

pulmonarydiseaseandcoronarydisease:COPDCoRi,asimpleandeffectivealgorithmfor

predicting the risk of coronary artery disease in COPD patients. Respir Med. 2015

Aug;109(8):1019-25

86) CazzolaM,RoglianiP,MateraMG.Cardiovasculardisease inpatientswithCOPD.Lancet

RespirMed.2015Aug;3(8):593-5

87) RoglianiP,LucàGandLauroD.Chronicobstructivepulmonarydiseaseanddiabetes.COPD

ResearchandPractice2015Aug;1:3DOI:10.1186/s40749-015-0005-y

88) Basello K, Pacifici F, Capuani B, Pastore D, LombardoM, Ferrelli F, Coppola A, Donadel

19Aprile2017 PaolaRogliani

G,ArrigaR,SconocchiaG,BelliaA,RoglianiP,FedericiM,SbracciaP,LauroD,Della-Morte

D. Serum- and Glucocorticoid-Inducible Kinase (SGK)1 delay the onset of Endothelial

SenescencebyDirectlyInteractingwithhTERT.RejuvenationRes.2016Feb;19(1):79-89

89) CazzolaM, CoppolaA,Rogliani P,MateraMG.Novel glucocorticoid receptor agonists in

thetreatmentofasthma.ExpertOpinInvestigDrugs.2015Nov;24(11):1473-82.

90) Cazzola M, Rogliani P, Ora J, Matera MG. Olodaterol + tiotropium bromide for the

treatment of chronic obstructive pulmonary disease. Expert Rev Clin Pharmacol.

2015;8(5):529-39.

91) Cazzola M, Calzetta L, Ora J, Puxeddu E, Rogliani P, Matera MG. Searching for the

synergisticeffectbetweenaclidiniumandformoterol:Frombenchtobedside.RespirMed.

2015Oct;109(10):1305-11.

92) Cazzola M, Rogliani P, Matera MG. Escalation and De-escalation of Therapy in COPD:

Myths,RealitiesandPerspectives.Drugs.2015Sep;75(14):1575-85.

93) CazzolaM,CalzettaL,PageC,JardimJ,ChuchalinAG,RoglianiP,MateraMG.Influenceof

N-acetylcysteineonchronicbronchitisorCOPDexacerbations:ametaanalysis.EurRespir

Rev.2015Sep;24(137):451-61.

94) Rogliani P, Matera MG, Cazzola M. Fluticasone furoate/vilanterol combination for the

treatmentofCOPDandasthma.DrugsToday(Barc).2015Aug;51(8):469-78.

95) LiccardiG,SalzilloA,CalzettaL,PignattiP,RoglianiP.

Canpetkeepingbeconsidered theonlycriterionofexposure tocat/dogallergens in the

firstyearoflife?AllergolImmunopathol(Madr).2015Nov16.pii:S0301-0546(15)00121-4.

96) BaselloK,PacificiF,CapuaniB,PastoreD,LombardoMF,FerrelliF,CoppolaA,DonadelG,

ArrigaR,SconocchiaG,BelliaA,RoglianiP,FedericiM,SbracciaP,LauroD,Della-MorteD.

Serum-andGlucocorticoid-InducibleKinase1Delay theOnsetofEndothelial Senescence

byDirectly InteractingwithHumanTelomeraseReverseTranscriptase.RejuvenationRes.

2016Feb;19(1):79-89.

97) LiccardiG,SalzilloA,CalzettaL,PignattiP,RoglianiP.Canpetkeepingbeconsideredthe

only criterion of exposure to cat/dog allergens in the first year of life? Allergol

Immunopathol(Madr).2016Jul-Aug;44(4):387-8.

98) CazzolaM,CalzettaL,RoglianiP,PuxedduE,FaccioloF,MateraMG.Interactionbetween

corticosteroidsandmuscarinicantagonistsinhumanairways.PulmPharmacolTher.2016

Feb;36:1-9.

19Aprile2017 PaolaRogliani

99) LiccardiG,SalzilloA,CalzettaL,PiccoloA,RoglianiP.Howmanysystemicreactionstoskin

pricktestscouldbepreventableindefinedconditions?AnnAllergyAsthmaImmunol.2016

Feb;116(2):174.

100) CazzolaM,RoglianiP,OraJ,MateraMG.Treatmentoptionsformoderate-to-verysevere

chronicobstructivepulmonarydisease.ExpertOpinPharmacother.2016;17(7):977-88.

101) CalzettaL,RoglianiP,MateraMG,CazzolaM.ASystematicReviewWithMeta-Analysisof

Dual Bronchodilation With LAMA/LABA for the Treatment of Stable COPD. Chest. 2016

May;149(5):1181-96.

102) Matera MG, Rogliani P, Calzetta L, Cazzola M. Safety Considerations with Dual

BronchodilatorTherapyinCOPD:AnUpdate.DrugSaf.2016Jun;39(6):501-8.

103) Liccardi G, Salzillo A, Calzetta L, Piccolo A, Menna G, Rogliani P. Can the presence of

cat/dogathomebeconsideredtheonlycriterionofexposuretocat/dogallergens?Alikely

underestimated bias in clinical practice and in large epidemiological studies. Eur Ann

AllergyClinImmunol.2016Mar;48(2):61-4.

104) LiccardiG,SalzilloA,CalzettaL,PiccoloA,RoglianiP.Chroniccatallergenexposureandlow

sensitization: Possible limitations in patient selection? J Allergy Clin Immunol. 2016

May;137(5):1621-2.

105) Cazzola M, Calzetta L, Rogliani P, Matera MG. The discovery of roflumilast for the

treatment of chronic obstructive pulmonary disease. Expert Opin Drug Discov. 2016

Jul;11(7):733-44.

106) D'AntonioS,RoglianiP,PaoneG,AltieriA,AlmaMG,CazzolaM,PuxedduE.Anunusual

outbreakofnontuberculousmycobacteria inhospital respiratorywards:Associationwith

nontuberculous mycobacterial colonization of hospital water supply network. Int J

Mycobacteriol.2016Jun;5(2):244-7.

107) LiccardiG,SalzilloA,CalzettaL,OraJ,RoglianiP.Dogallergenimmunotherapyandallergy

tofurryanimals.AnnAllergyAsthmaImmunol.2016Jun;116(6):590.

108) RoglianiP,CalzettaL,CazzolaM,MateraMG.Drugsafetyevaluationofroflumilastforthe

treatmentofCOPD:ameta-analysis.ExpertOpinDrugSaf.2016Aug;15(8):1133-46.

109) Salvati,A.,Ora,J.,Donatucci,B.,Rogliani,P.Cardiopulmonaryexercisetestinathletesand

coronarydiseasesMedicinadelloSport69(2)June2016,289-296

110) CazzolaM,CalzettaL,PuxedduE,OraJ,FaccioloF,RoglianiP,MateraMG.Pharmacological

characterisation of the interaction between glycopyrronium bromide and indacaterol

19Aprile2017 PaolaRogliani

fumarate in human isolated bronchi, small airways and bronchial epithelial cells. Respir

Res.2016Jun13;17(1):70.

111) Liccardi G, Salzillo A, Calzetta L, Piccolo A, Rogliani P. Assessment of pet exposure by

questionnairesinepidemiologicalstudies(butalsoinclinicalpractice!):Whythequestions

shouldbesimplified?JAsthma.2016Nov;53(9):879-81.

112) Cazzola M, Ora J, Di Paolo A, Puxeddu E, Calzetta L, Rogliani P. Onset of action of

budesonide/formoterolSpiromax(®)comparedwithbudesonide/formoterolTurbuhaler(®)

inpatientswithCOPD.PulmPharmacolTher.2016Aug;39:48-53.

113) CazzolaM,Rogliani P. Dowe really need asthma-chronic obstructive pulmonary disease

overlapsyndrome?JAllergyClinImmunol.2016Oct;138(4):977-983.

114) LiccardiG,SalzilloA,CalzettaL,OraJ,CazzolaM,MateraMG,RoglianiP.Cananincreased

cholinergictoneconstituteapredictorofpositiveresponsetotiotropiuminpatientswith

moderateasthma?JAllergyClinImmunolPract.2016Jul-Aug;4(4):791-3.

115) Liccardi G, Salzillo A, Piccolo A, Calzetta L,Rogliani P. Dysfunction of small airways and

prevalence, airway responsiveness and inflammation in asthma: much more than small

particlesizeofpetanimalallergens.UpsJMedSci.2016Aug;121(3):196-7.

116) RoglianiP,CalzettaL,CapuaniB,FaccioloF,CazzolaM,LauroD,MateraMG.Glucagon-Like

Peptide 1 Receptor: A Novel Pharmacological Target for Treating Human Bronchial

Hyperresponsiveness.AmJRespirCellMolBiol.2016Dec;55(6):804-814.

117) CalzettaL,OrlandiA,PageC,RoglianiP,RinaldiB,RosanoG,CazzolaM,MateraMG.Brain

natriureticpeptide:Muchmorethanabiomarker.IntJCardiol.2016Oct15;221:1031-8.

118) CapuaniB,PacificiF,PastoreD,PalmirottaR,DonadelG,ArrigaR,BelliaA,DiDanieleN,

RoglianiP,AbeteP,SbracciaP,GuadagniF,LauroD,Della-MorteD.TheroleofepsilonPKC

in acute and chronic diseases: Possible pharmacological implications of its modulators.

PharmacolRes.2016Sep;111:659-67.

119) Rogliani P, Calzetta L, Cavalli F,MateraMG, CazzolaM. Pirfenidone, nintedanib and N-

acetylcysteineforthetreatmentofidiopathicpulmonaryfibrosis:Asystematicreviewand

meta-analysis.PulmPharmacolTher.2016Oct;40:95-103.

120) LiccardiG,SalzilloA,CalzettaL,CazzolaM,MateraMG,RoglianiP.Canbronchialasthma

withanhighlyprevalentairway (andsystemic)vagal tonebeconsideredan independent

asthmaphenotype?Possibleroleofanticholinergics.RespirMed.2016Aug;117:150-3.

121) BlasiF,PageC,RossoliniGM,PallecchiL,MateraMG,RoglianiP,CazzolaM.Theeffectof

19Aprile2017 PaolaRogliani

N-acetylcysteineonbiofilms:Implicationsforthetreatmentofrespiratorytractinfections.

RespirMed.2016Aug;117:190-7.

122) MateraMG,PageC,RoglianiP,CalzettaL,CazzolaM.TherapeuticMonoclonalAntibodies

fortheTreatmentofChronicObstructivePulmonaryDisease.Drugs.2016Sep;76(13):1257-

70.

123) Liccardi G, Calzetta L, Sapio C,Rogliani P. Occupational allergy to horse allergens:More

thanexposuretohorses!IntJOccupMedEnvironHealth.2016;29(5):721-3.

124) Liccardi G, Salzillo A, Calzetta L, Ora J, Rogliani P. Gastroesophageal reflux and COPD

exacerbations: Is cholinergic-mediated oesophago-bronchial reflex a possible link?

Respirology.2016Sep16

125) CazzolaM,Rogliani P. LABA/LAMA combinations instead of LABA/ICS combinationsmay

prevent or delay exacerbations of COPD in some patients. Evid Based Med. 2016

Dec;21(6):222.

126) RoglianiP,PuxedduE,CiapriniC,OraJ,OnoratoA,PezzutoG,CalzettaL,CazzolaM.The

TimeCourseofPulmonaryFunctionTestsinCOPDPatientswithDifferentLevelsofBlood

Eosinophils.BiomedResInt.2016;2016:4547953.

127) RoglianiP,OraJ,PuxedduE,CazzolaM.Airflowobstruction:isitasthmaorisitCOPD?IntJ

ChronObstructPulmonDis.2016Nov30;11:3007-3013.

128) LiccardiG,SalzilloA,CalzettaL,PiccoloA,PuxedduE,RoglianiP.IsAllergicSensitizationto

Siberian Hamster Preventable in High-Risk Individuals Who Are Already Sensitized or

ExposedtoFurryAnimals?JInvestigAllergolClinImmunol.2016;26(6):403-405.

129) TacconiF,RoglianiP,CristinoB,GilardiF,PalombiL,PompeoE;AwakeThoracicSurgery

ResearchGroup..Minimalistvideo-assistedthoracicsurgerybiopsyofmediastinaltumors.J

ThoracDis.2016Dec;8(12):3704-3710

130) CalzettaL,RoglianiP,OraJ,PuxedduE,CazzolaM,MateraMG.LABA/LAMAcombination

in COPD: a meta-analysis on the duration of treatment. Eur Respir Rev. 2017 Jan

17;26(143).

131) CazzolaM,CalzettaL,FaccioloF,RoglianiP,MateraMG.Pharmacologicalinvestigationon

theanti-oxidantandanti-inflammatoryactivityofN-acetylcysteineinanexvivomodelof

COPDexacerbation.RespirRes.2017Jan24;18(1):26

132) CazzolaM,OraJ,RoglianiP,MateraMG.Roleofmuscarinicantagonistsinasthmatherapy.

ExpertRevRespirMed.2017Mar;11(3):239-253

19Aprile2017 PaolaRogliani

133) Cazzola M, Calzetta L, Rogliani P, Matera MG. Tiotropium formulations and safety: a

networkmeta-analysis.TherAdvDrugSaf.2017Jan;8(1):17-30

134) Puxeddu E, Cavalli F, Pezzuto G, Teodori E, Rogliani P. Impact of pulmonary vascular

volume on mortality in IPF: is it time to reconsider the role of vasculature in disease

pathogenesisandprogression?EurRespirJ.2017Feb23;49(2)

135) Cazzola M, Calzetta L, Rogliani P, Matera MG. The Challenges of PrecisionMedicine in

COPD.MolDiagnTher.2017Feb28

136) Liccardi G, Calzetta L, Salzillo A, Apicella G, Cavalli F, Rogliani P. Is H1-antihistamine

(desloratadine 5 mg, orodispersible tablet) premedication in NSAID-associated urticaria

really safe and practicable in "real life"? J Allergy Clin Immunol Pract. 2017 Mar -

Apr;5(2):535

137) Rogliani P, Calzetta L, Coppola A, Cavalli F, Ora J, Puxeddu E, Matera MG, Cazzola M.

OptimizingdrugdeliveryinCOPD:Theroleofinhalerdevices.RespirMed.2017Mar;124:6-

14

138) Liccardi G, Calzetta L, Salzillo A, Puxeddu E, Rogliani P. Relationship between

oxytocin/vasopressinandlatexinobstetricsurgery:howtorecognize(andprevent)allergic

reactionsanddifferentiatethemfromsideeffects?JAllergyClinImmunolPract.2017Mar

9

139) LiccardiG,CalzettaL,SalzilloA,BilleriL,LucàG,RoglianiP.LettertotheEditor:Candog

allergenimmunotherapyreduceconcomitantallergicsensitizationtootherfurryanimals?

Apreliminaryexperience.EurAnnAllergyClinImmunol.2017Mar;49(2):92-96

140) CalzettaL,RoncadaP,diCaveD,BonizziL,UrbaniA,PistocchiniE,RoglianiP,MateraMG.

Pharmacological treatments in asthma-affected horses: A pair-wise and network meta-

analysis.EquineVetJ.2017Mar10

141) BraidoF, IlariaB,AlleriP,BacciE,BarbettaC,BellocchiaM,BenfanteA,BlasiF,BuccaC,

BuscetiMT,CentanniS,ColanardiMC,ContoliM,CorsicoA,D'AmatoM,DiMarcoF,Marco

D,FerrariM,FlorioG,FoisAG,FoschinoBarbaroMP,SilviaG,GirbinoG,GrossoA,Latorre

M,ManiscalcoS,MazzaF,MereuC,MolinengoG,Ora J,PaggiaroP,PatellaV,PelaiaG,

Pirina P, ProiettoA,Rogliani P, Santus P, ScichiloneN, Simioli F, Solidoro P, Terraneo S,

ZucconU,CanonicaGW.Asthmamanagement inaspecialistsetting:ResultsofanItalian

RespiratorySocietysurvey.PulmPharmacolTher.2017Mar21

142) CazzolaM,CalzettaL,RinaldiB,PageC,RosanoG,RoglianiP,MateraMG.Managementof

19Aprile2017 PaolaRogliani

Chronic Obstructive Pulmonary Disease in Patients with Cardiovascular Diseases. Drugs.

2017Mar28

143) PicaF,CiottiM,MauriciM,BuèC,NardiP,LucàG,MoroniG,RoglianiP,PernoCF,VolpiA.

Clinical features and outcome of hospitalized patients with HSV-1 DNA in the lower

respiratorytract.NewMicrobiol.2017Apr3;40(2)

144) Liccardi G, Calzetta L, Salzillo A, Piccolo A, Pane G, Rogliani P. Can a better patient

phenotyping predict the efficacy of tiotropium in asthmatic adolescents? Expert Opin

Pharmacother.2017Apr11

Contributoinvolume(CapitolooSaggio)

• RoglianiP,SegretiA,CazzolaM(2014).Chapter:15.AdultCardiacConditions.In:RichardF.

Lockey,MD,DennisK.Ledford,MD,andWithWAO.(acuradi):OXFORDPRESS,Asthma.

Comorbidities,CoexistingConditions,andDifferentialDiagnosis.

• RoglianiP,CiapriniC(2013).ILPAZIENTEFUMATORE.In:BreviarioMedico.Pavia:Selecta

Medica

• Frasca L, Ambrogi V,Rogliani P, Saltini C and Pompeo E (2012). Awake Lung Biopsy for

InterstitialLungDisease.In(acuradi):EugenioPompeo,AwakeThoracicSurgery.p.105-

118,London:BenthamEbooks,ISBN:978-1-60805-288-2